Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

anti-SARS-CoV-2 monoclonal antibody AZD3152

A long-acting neutralizing human monoclonal antibody derived from B cells of convalescent patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and directed against SARS-CoV-2, that can potentially be used for passive immunization against Coronavirus disease 2019 (COVID-19). Upon administration, anti-SARS-CoV-2 monoclonal antibody AZD3152 neutralizes SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:AZD 3152
AZD-3152
AZD3152
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search